MedTrace Logo

Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression

NCT00322764 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2007-11-09

No results posted yet for this study

Summary

The primary purpose of this study is to determine the safety and efficacy of oral RG2417 (Uridine) when administered to patients with Bipolar I depression twice daily for six weeks.

Conditions

Interventions

DRUG

Uridine

Sponsors & Collaborators

  • Repligen Corporation

    lead INDUSTRY

Principal Investigators

  • David Jacoby, MD, PhD · Repligen Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00322764 on ClinicalTrials.gov